APA-viite (7. p.)

Burmester, G. R., Coates, L. C., Cohen, S. B., Tanaka, Y., Vranic, I., Nagy, E., . . . Kinch, C. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare.

Chicago-viite (17. p.)

Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.

MLA-viite (9. p.)

Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.